Sensus Healthcare, Inc. Announces Pricing of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 13, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has priced an underwritten public offering of 2,205,882 shares of its common stock, par value $0.01 per share, at a public offering price of $6.80 per share. Sensus has granted a 30-day option to purchase up to an additional […]
Sensus Healthcare, Inc. Announces Commencement of Public Offering of Common Stock
BOCA RATON, Fla., Sept. 12, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it commenced a public offering of its common stock, par value $0.01 per share. B. Riley FBR is serving as the lead underwriter and sole book-running manager for the offering. Sensus intends to use the net proceeds from the offering […]
Sensus Healthcare Presents at National Cancer Care Alliance Leadership Board and Practice Quarterly Meeting
BOCA RATON, Fla., Sept. 7, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, participated at the National Cancer Care Alliance (NCCA) Leadership Board and Practice Quarterly […]
Sensus Healthcare to Participate in Two Upcoming Investor Conferences
BOCA RATON, Fla., Aug. 27, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018, as follows: Annual B. […]
Sensus Healthcare Second Quarter Financial Results Feature Continued Strong Revenue Growth
Ships 21 systems including 12 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three […]
Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radio Therapy for Treating Non-Melanoma Skin Cancer and Keloids
SRT-100+ Offers Advanced Features for Patients and Doctors, Including Remote Diagnostics and Patient Medical Records Integration, as Well as Core System Enhancements BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy […]
Sensus Healthcare CEO Receives “Innovator of the Year” Award at The Aesthetic Show 2018
Sensus Also Named Runner-Up “Company Innovator of the Year” BOCA RATON, Fla., July 31, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the Company’s CEO, Joe Sardano, has been named non-physician, […]
Sensus Healthcare to Host Second Quarter 2018 Financial Results and Business Update Conference Call on August 2, 2018
BOCA RATON, Fla., July 24, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, August 2, 2018 at 4:30 p.m. Eastern time to discuss the financial results […]
Sensus Healthcare Announces Strategic Agreement with SkinCure Oncology
SkinCure Provides Turnkey Solution for Sensus’ SRT-100 Vision™, Aimed at Dermatology Community BOCA RATON, Fla., July 12, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced a strategic agreement focused on marketing the […]
Sensus Healthcare and CellMark Medical Partner to Accelerate International Expansion and Growth for Innovative Oncology and Aesthetic Solutions
BOCA RATON, Fla., July 10, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), and CellMark Medical, a global supply chain service company, today announced a new partnership to support and accelerate international growth and encourage worldwide […]
